ADXS Board of Directors, please consider putting the company on the auction block and selling for $20 to $25 ($800 million to $1 billion valuation). Arguably, this would be in the best interest of 1) patients (getting the constructs to market faster with trial execution done by the expertise of a larger pharma or biotech) and 2) ADXS investors (who are down 50% from the recapitalization price of $12 over the last four years). Why risk putting into place another CEO who turns out to fumble in advancing the platform (Moore) or one who turns out to be unethical and puts his personal financial interests above shareholder interests (O'Connor). In the latest corporate presentation, you cite around $1 billion of potential future deal value based on current collaborations - you should be able to sell the entire company for approximately this value ($20 to $25 share price). Do what's right for the company, its patients and investors.